Embryo scoring

In the past few years, startups have begun offering a new form of the technology called PGT-P, or preimplantation genetic testing for polygenic disorders (and, some claim, traits). These are conditions and characteristics that arise out of interactions among hundreds or thousands of genetic variants. The resulting polygenic risk scores offer statistical probabilities that an embryo will develop, say, brown eyes or a high IQ or short stature, presenting potential parents with a way to sift through their “best embryos.”

A company called Genomic Prediction introduced the first clinical application of PGT-P back in 2019. It was followed a few years later by Orchid, which offered a more comprehensive type of sequencing. As they have commercialized, both companies have focused primarily on severe diseases. Then, in 2025, two new competitors—Herasight and Nucleus Genomics—started making bold claims about a wide range of characteristics they could screen for, including intelligence.

Perhaps unsurprisingly, this new kind of testing—which can cost up to $50,000—is incredibly controversial. Some critics warn of eugenics, while others question the clinical utility of these scores. Even proponents acknowledge that they offer probabilities of somewhat limited significance, rather than certainties.

Nevertheless, the practice has grown popular in Silicon Valley, where tech titans like Elon Musk and Peter Thiel have supported companies offering it. Now it’s becoming more widely available to everyone: Today, PGT-P is offered at over 100 fertility clinics in the US. This competition could drive down prices, expand availability, and improve the quality of all PGT services.